Abstract:The antitumor efficacy of tumor vaccines is often limited by weak T cell responses and poor activated T cells infiltration. Herein, we reported a novel synergistic strategy to simultaneously overcome these two obstacles to realize enhanced tumor elimination. To induce the robust T cell responses, we designed a minimalist tumor nanovaccine based on stepwise electrostatic interactions. The dual-functional delivery system PEI/CaCO3 (polyethylenimine coated CaCO3), could not only act as a vaccine carrier that absorbed antigen ovalbumin (OVA) and adjuvant unmethylated cytosine-phosphate-guanine (CpG) with high efficiency, but also work as an underlying adjuvant to activate bone marrow-derived dendritic cells (BMDCs). Therefore, the formed PEI/CaCO3/OVA/CpG vaccines (NVs) realized the significant enhancement of both the BMDCs activation and the specific responses of T cells in vivo. In addition, to enhance the infiltration of activated T cells in the tumor sites, the Spam1 gene, which could express hyaluronidase (HAase), was explored using PEI as the gene carrier shielded with aldehyde modified polyethylene glycol (CHO-PEG-CHO) through pH responsive Schiff base bonds. PEG/PEI/pSpam1 (p) could achieve a high HAase expression in the tumor sites to further degrade the tumor extracellular matrix, thus promoting the infiltration of immune cells. Besides, the degradation of extracellular matrix increased blood perfusion and relieved the tumor hypoxia to modulate the immune-suppressive microenvironment. Highly enhanced antitumor efficiency and tumor re-challenge prevention were achieved by combined NVs with p in B16-OVA bearing mice. The facile synergistic strategy we presented here is expected to be further used for personalized immunotherapy in the future.

Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model.

Constructing Tumor Vaccines Targeting for Vascular Endothelial Growth Factor (vegf) by Dna Shuffling

Combination Therapy of Hepatocellular Carcinoma by DNA Shuffling-Based VEGF Vaccine and Doxorubicin

Immunotherapy of EGFR-positive Tumor Based on Recombinant EGFR Phage Vaccine

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Combination Therapy Of Vegf-Trap And Gemcitabine Results In Improved Anti-Tumor Efficacy In A Mouse Lung Cancer Model

Combination of Low-Dose Gemcitabine and Recombinant Quail Vascular Endothelial Growth Factor Receptor-2 As a Vaccine Induces Synergistic Antitumor Activities

Immunotherapy effect on tumor and recombination of VGFR phage vaccine

[Immunotherapeutic Effect of Recombinant EGFR Phage Vaccine on Tumors].

Antitumor Effects of Immunotherapy with Xenogeneic VEGF Vaccine Combined with Chemotherapy on Solid Tumor in Mice

Active Immunotherapy for Mouse Breast Cancer with Irradiated Whole-Cell Vaccine Expressing VEGFR2.

Antitumor effects of recombinant quail vascular endothelial growth factor receptor 2, as a vaccine, combined with cisplatin on LL/2 tumor model in mice]

Anti-tumor Effect of Tumor Vaccine Combined with Metronomic Chemotherapy on Breast Cancer in Mice

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.

Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger

Combining TGF-beta 1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine

Immunotherapy Of Tumors With Vaccine Based On Quail Homologous Vascular Endothelial Growth Factor Receptor-2

Immunogenicity and Efficacy of a Rationally Designed Vaccine Against Vascular Endothelial Growth Factor in Mouse Solid Tumor Models

Combination of Low‐dose Cisplatin and Recombinant Xenogeneic Endoglin As a Vaccine Induces Synergistic Antitumor Activities

The Immunogenicity and Anti-Tumor Efficacy of a Rationally Designed EGFR Vaccine